Cantor Fitzgerald Forecasts ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a report issued on Tuesday, February 25th. Cantor Fitzgerald analyst L. Watsek forecasts that the biotechnology company will earn ($2.72) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $200.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share.

ASND has been the subject of a number of other research reports. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Stifel Nicolaus increased their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Oppenheimer cut their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Stock Up 0.7 %

Shares of NASDAQ ASND opened at $152.61 on Thursday. The business has a 50 day moving average price of $135.40 and a two-hundred day moving average price of $133.67. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $158.06. The firm has a market cap of $9.26 billion, a PE ratio of -21.49 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ascendis Pharma A/S during the fourth quarter worth approximately $28,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth $30,000. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 197 shares during the period. Blue Trust Inc. boosted its stake in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares in the last quarter. Finally, Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the third quarter valued at about $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.